Paolo Springhetti

Paolo Springhetti, a Milanese cardiologist specializing in transcatheter valve therapies, joins Marie-Annick Clavel to discuss the LANDMARK trial findings. They dive into the unique sizing advantages of Myval compared to competitors, highlighting impressive hemodynamic outcomes. Sex-specific definitions of patient-prosthesis mismatch (PPM) come under scrutiny, revealing stark differences among valve types. The duo also explores the implications of Myval's low-flow recovery and durability concerns for younger patients, emphasizing the need for long-term studies.